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AbstrAct
Objectives To assess the benefits and harms of exercise 
in patients with depression.
Design Systematic review
Data sources Bibliographical databases were searched 
until 20 June 2017.
Eligibility criteria and outcomes Eligible trials 
were randomised clinical trials assessing the effect 
of exercise in participants diagnosed with depression. 
Primary outcomes were depression severity, lack of 
remission and serious adverse events (eg, suicide) 
assessed at the end of the intervention. Secondary 
outcomes were quality of life and adverse events 
such as injuries, as well as assessment of depression 
severity and lack of remission during follow-up after the 
intervention.
results Thirty-five trials enrolling 2498 participants 
were included. The effect of exercise versus control 
on depression severity was −0.66 standardised mean 
difference (SMD) (95% CI −0.86 to −0.46; p<0.001; 
grading of recommendations assessment, development 
and evaluation (GRADE): very low quality). Restricting 
this analysis to the four trials that seemed less affected 
of bias, the effect vanished into −0.11 SMD (−0.41 to 
0.18; p=0.45; GRADE: low quality). Exercise decreased 
the relative risk of no remission to 0.78 (0.68 to 0.90; 
p<0.001; GRADE: very low quality). Restricting this 
analysis to the two trials that seemed less affected 
of bias, the effect vanished into 0.95 (0.74 to 1.23; 
p=0.78). Trial sequential analysis excluded random 
error when all trials were analysed, but not if focusing 
on trials less affected of bias. Subgroup analyses found 
that trial size and intervention duration were inversely 
associated with effect size for both depression severity 
and lack of remission. There was no significant effect of 
exercise on secondary outcomes.
conclusions Trials with less risk of bias suggested 
no antidepressant effects of exercise and there were 
no significant effects of exercise on quality of life, 
depression severity or lack of remission during follow-
up. Data for serious adverse events and adverse 
events were scarce not allowing conclusions for these 
outcomes.
systematic review registration The protocol was 
published in the journal Systematic Reviews: 2015; 4:40.
IntrODuctIOn
Depression is a common disorder affecting 
up to 17% of the population during their life-
time.1 2 Based on data from WHO, depression 
is ranked as the second largest healthcare 
problem globally, in terms of years lived with 
disability.3 Depending on its severity, depres-
sion is often treated using psychotherapy, 
antidepressants or a combination of both. 
However, the clinical benefits of antidepres-
sants4–6 and psychotherapy7–9 has been chal-
lenged. Both treatments are costly in terms of 
time and money and may also have adverse 
effects. Compliance with antidepressant 
treatment is poor; the dropout rate in clinical 
trials is reported to be between 12% and 40% 
within the initial 6–8 weeks of treatment.4 10
The weakness of evidence for the bene-
ficial effect of current interventions, along 
with problems related to low compliance 
and harms, has resulted in an interest in 
using alternative interventions. The use of 
exercise as an intervention has attracted 
considerable attention, and various forms 
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strengths and limitations of this study
 ► The protocol for this review has previously been 
published.
 ► Using meta-regression analysis, trial sequential 
analysis and the grading of recommendations 
assessment, development and evaluation system, 
the conclusions from this review is based on a firm 
and transparent platform.
 ► Based on an extensive literature search, this 
review included 35 trials allocating almost 2500 
participants diagnosed with depression to exercise 
or control interventions than could be analysed.
 ► The effect estimates are largely based on trials at 
high risk of bias.
 ► Effect estimates from included trials had 
considerable heterogeneity.
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of exercise varying in intensity have been assessed in a 
number of randomised clinical trials to test their effec-
tiveness as a treatment for patients with depression. In 
2011, we published a meta-analysis of randomised clin-
ical trials examining the effect of exercise on depres-
sive symptoms in patients with clinical depression.11 
The results suggested that referring patients with clin-
ical depression to exercise programme was associated 
with a small-to-moderate effect on depressive symptoms. 
However, restricting the analysis to three trials at low 
risk of bias, the effect estimate was non-significant. Since 
2011, other reviews have been published on the effect 
of exercise on depressive symptoms,12 in older people,13 
and in patients with chronic illnesses.14 However, none of 
these reviews addressed the specific population of adults 
diagnosed with major depression according to valid diag-
nostic criteria, such as the International Classification 
of Diseases15 or the Diagnostic and Statistical Manual of 
Mental Disorders.16 The reviews contained a number of 
trials that included volunteers who were defined as being 
depressed on the basis of psychometric testing (eg, Beck 
Depression Inventory17), as opposed to individuals with 
a clinical diagnosis of major depression. Furthermore, 
several randomised clinical trials investigating the effect 
of exercise in clinically depressed individuals have been 
published since our 2011 review.11
The objectives of the present systematic review are to 
investigate the beneficial and harmful effects of exer-
cise, in terms of severity of depression, lack of remission, 
quality of life and suicide versus controls with or without 
co-interventions in adults with a clinical diagnosis of major 
depression. The current systematic review differs from our 
previous review in a number of aspects.11 We only consid-
ered trials including participants diagnosed with depres-
sion according to a validated diagnostic system. We also 
included trials including participants with somatic comor-
bidity, for example, cancer or diabetes. The harmful 
effects of exercise interventions are also addressed, the 
intervention effects being assessed according to the 
grading of recommendations assessment, development 
and evaluation (GRADE) framework, and bibliographical 
searches have been extended to include a Chinese and a 
South American database until 2016.
MEthODs/DEsIgn
The protocol for this review has previously been 
published.18
search strategy
The following bibliographical databases was searched: 
CENTRAL, MEDLINE, EMBASE, Science Citation Index 
(Web of Science), LILACS and Wanfang using medical 
subject headings (MeSH or similar) when possible or text 
word terms: depression, depressive disorder and exercise, 
aerobic, non-aerobic, physical activity, physical fitness, 
walking, jogging, running, bicycling, swimming, strength 
or resistance (see online supplementary material S1 for 
an example of a bibliographical search). The main search 
was conducted in August 2015, and the latest search was 
conducted on 20 June 2017.
trial selection
One investigator (JK) examined titles and abstracts to 
remove obviously irrelevant reports. Two investigators 
(JK+HS) examined full-text reports and abstracts deter-
mining compliance with inclusion criteria. A trial was 
considered eligible if it was a randomised clinical trial 
including participants diagnosed as having major depres-
sion according to a valid and recognised diagnostic 
system (ie, Research Diagnostic Criteria,19 International 
Classification of Diseases (ICD)15 or Diagnostic and Statis-
tical Manual of Mental disorders (DSM)16 and included 
participants aged >17 years. Abstracts and full-text reports 
were included.
Trials were excluded if they measured depression imme-
diately after a single bout of exercise, compared one form 
of exercise versus another, or compared different exer-
cise intensities without including a control group. The 
trials had to allocate participants to an exercise inter-
vention versus a control group (ie, exercise vs a control 
group receiving no intervention or treatment as usual or 
an attention control using light exercise) or using exer-
cise as an add-on treatment (ie, exercise plus usual treat-
ment in the experimental group vs usual treatment alone 
in the control group). Exercise intervention was defined 
as a systematic physical intervention with the intention to 
increase muscle strength and/or cardiovascular fitness, 
for example, running, swimming or weight lifting. In case 
of attention control, it should specifically be mentioned 
by the authors of the trial report that the intervention was 
intended as a control intervention.
Outcomes
The primary outcomes were: 1) depressive symptoms 
measured on a continuous scale assessed at the end of 
the intervention; 2) lack of remission, that is, a binary 
outcome of the proportion of participants in each inter-
vention group of the trial who did not obtain remission 
at the end of the intervention according to the authors’ 
own definition and 3) serious adverse events defined 
according to International Council for Harmonisation, 
Good Clinical Practice (ICH-GCP) as any untoward 
medical occurrence that was life threatening, resulted 
in death or persistent or significant disability (ICH-GCP 
1997).20 Serious adverse events accordingly include 
suicide attempts as well as suicides. The secondary 
outcomes were quality of life, non-serious adverse events 
(eg, muscle injuries) as well as depressive symptoms and 
lack of remission assessed after the intervention.
Data extraction
Two authors (JK, HS) independently extracted data 
using a prepiloted structured form. Any discrepancies in 
the data extraction or inclusion/exclusion of trials was 
resolved by referring to the original papers. CG or MN 
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assisted as adjudicator in cases of disagreements. Data 
extraction included, in addition to outcomes, informa-
tion regarding country of origin, number of randomised 
participants, number of participants included in efficacy 
analysis, mean age of participants, diagnostic system, 
baseline assessment of depression severity, type of inter-
vention, frequency of intervention and duration of 
intervention. Continuous outcomes were preferred in 
the following order: postintervention scores with corre-
sponding SD, mean change from baseline with SD, mean 
difference between groups postintervention and reported 
outcomes were preferred to figures. JK and CH inde-
pendently performed the assessment of bias domains. 
The authors JK, CG and MN have previously published 
trial reports assessing the effect of exercise in participants 
with depression,21 22 and to reduce the risk of academic 
bias two additional authors were included in the current 
systematic review (CH, HS).
risk of bias assessment
Definitions in the assessment of bias risk of a trial was 
conducted according to the Cochrane Handbook for 
Systematic Reviews of Interventions23 of the following 
domains: allocation sequence generation, allocation 
concealment, blinding of participants and personnel, 
blinding of outcome assessors, incomplete outcome data, 
selective outcome reporting, for-profit bias and other 
bias. Trials assessed as having ‘low risk of bias’ in all of 
the above specified domains were considered ‘trials at low 
risk of bias’. Trials assessed as having ‘uncertain risk of 
bias’ or ‘high risk of bias’ in one or more of the above 
specified domains were considered trials at ‘high risk of 
bias’. In line with our previous systematic review11 and the 
latest Cochrane review on exercise for depression,24 trials 
at low risk of bias in the allocation concealment domain, 
blinded outcome assessment domain and the incomplete 
outcome data domain were characterised as ‘trials poten-
tially having less risk of bias than other trials at high risk 
of bias’. Trials assessing the effect of behavioural interven-
tions are rarely able to mask the allocation, and partici-
pants and healthcare providers are therefore not blinded. 
Therefore, we will also report the number of trials at low 
risk of bias in the remaining domains.
Data synthesis and analysis
In order to be able to include all of the trials in our 
meta-analysis, estimates of standardised mean difference 
(SMD) for each individual trial was carried out. SMD is 
the mean difference in depression score between the 
exercise and control groups divided by the pooled SD at 
follow-up. The result is a unit-free effect size. By conven-
tion, SMD effect sizes of 0.2, 0.5 and 0.8 are considered 
small, medium and large intervention effects.23 For 
dichotomous variables, we calculated the risk ratio (RR) 
with a 95% CI. It was expected that some trials would 
have several intervention groups. Data from the experi-
mental groups were pooled and compared with the data 
from the control group. In case of discrepancies between 
the random-effects model analysis and the fixed-effect 
model analysis, both results are reported; otherwise, only 
results from the random-effects analysis are reported. 
The degree of heterogeneity was quantified using the 
I2 statistic,25 which can be interpreted as the percentage 
of variation observed between the trials attributable to 
between-trial differences, rather than sampling error 
(chance). Heterogeneity was explored by analyses of 
subgroups (see below).
For the primary outcomes, trial sequential analysis was 
performed.26 27 In order to calculate the required infor-
mation size and the cumulative Z-curve’s eventual breach 
of relevant trial sequential monitoring boundaries, the 
required information size for the primary continuous 
outcome was based on type I error of 5%, a beta of 10%, 
the SE of the meta-analysis and a minimal difference 
of three points on the Hamilton Depression Scale, 17 
items (HAM-D17).
18 Post hoc we calculated the required 
information size including all trials. This was done by 
converting effect estimates from trials reporting other 
outcome scales into the HAM-D17 scale as described by 
Thorlund et al.28 In order to calculate the required infor-
mation size and the cumulative Z-curve’s eventual breach 
of relevant trial sequential monitoring boundaries, the 
required information size for lack of remission was based 
on type I error of 5%, a beta of 10%, the proportion of 
participants in the control group with the outcome and a 
relative risk reduction of 15% and 30%.
Bayes factors were calculated for all primary outcomes.29 
Low p values suggest that we can reject the null-hypoth-
esis. But even a low p value from a meta-analysis can be 
misleading if there is also a low probability that data are 
compatible with the anticipated intervention effect. In 
other words, the probability that the actual measured 
difference in effect of the compared interventions resulted 
from an a priori anticipated ‘true’ difference needs to be 
considered. For this purpose, it is helpful to calculate the 
Bayes factor, which is the ratio of the p value probabilities 
of the meta-analysis result divided by the probability of 
the anticipated effect, or ‘true’ effect.29 As suggested by 
Jakobsen et al,29 a Bayes factor <0.1 together with a low 
p value suggest, if bias can be ruled out, that the observed 
result is compatible with the a priori expected effect. If 
the Bayes factor is >0.1, the result is not compatible with 
the a priori expected effect and the effect may be lower.
To assess the potential impact of missing data (incom-
plete outcome data bias), we did sensitivity analysis of 
missing data using the following strategy: a ‘best-worst’ 
case scenario was assessed, assuming that all participants 
lost to follow-up in the intervention group had a bene-
ficial outcome (the group mean minus 1 SD), and all 
those with missing outcomes in the control group have 
had a harmful outcome (the group mean plus 1 SD and 
2 SD). In addition, the reverse ‘worst-best-case’ scenario 
analysis was also performed.29 Missing data for the ‘lack 
of remission’ outcome were imputed in sensitivity analysis 
according to the following scenarios30: 1) poor outcome 
analysis: assuming that all of the drop-outs/participants 
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lost from both the experimental and the control arms 
experienced the outcome, including all randomised 
participants in the denominator; 2) good outcome anal-
ysis: assuming that none of the drop-outs/participants lost 
from the experimental and the control arms experienced 
the outcome, including all randomised participants in 
the denominator; 3) extreme case analysis favouring the 
experimental intervention (‘best-worse’ case scenario): 
none of the drop-outs/participants lost from the exper-
imental arm, but all of the drop-outs/participants lost 
from the control arm experienced the outcome, including 
all randomised participants in the denominator and 4) 
extreme case analysis favouring the control (‘worst-best’ 
case scenario): all of the drop-outs/participants lost 
from the experimental arm, but none from the control 
arm experienced the outcome, including all randomised 
participants in the denominator.
subgroup analyses
In subgroup analyses, the possible effects of variables 
on intervention effects on outcomes and heterogeneity 
were compared. Trials potentially having less risk of bias 
(ie, trials with adequate allocation concealment, blinded 
outcome assessment and intention-to-treat analysis) were 
compared with trials at high risk of bias. The effect of age 
was assessed by comparing trials including older partic-
ipants (mean age >59 years) to trials including younger 
participants (mean age <60 years). The effect of type of 
exercise was assessed by comparing trials using group 
exercises compared with trials using individual exercise. 
The effect of duration of intervention was assessed by 
comparing trials with short duration of intervention to 
trials with long duration of intervention splitting by the 
median time of duration. The effect of type of control 
group was assessed by comparing trials using attention 
control to trials with waitlist controls and comparing trials 
with exercise as add-on to medication to trials not using 
any medication. In addition, a within-study comparison of 
low-dose exercise versus high-dose exercise in trials using 
different exercise intensities was performed. The effect 
of comorbid somatic disease was assessed by comparing 
the effect estimates from trials including participants with 
depression compared with trials including participants 
with depression in addition to a somatic disease. Publi-
cation bias was assessed by visual inspection of a funnel 
plot and by Egger’s test and if publication bias plau-
sible Duval’s and Tweedie’s trim and fill procedure was 
conducted.31
We assessed and graded the evidence according to 
the GRADE for high risk of bias, imprecision, indirect-
ness, heterogeneity and publication bias.32 Based on this 
assessment, the intervention was graded accordingly: 
‘high quality’—we are very confident that the true effect 
lies close to that of the estimate of the effect; ‘moderate 
quality’—we are moderately confident in the effect esti-
mate. The true effect is likely to be close to the estimate 
of the effect, but there is a possibility that it is substan-
tially different; ‘low quality’—our confidence in the 
effect estimate is limited: the true effect may be substan-
tially different from the estimate of the effect; ‘very low 
quality’—we have very little confidence in the effect esti-
mate: the true effect is likely to be substantially different 
from the estimate of the effect.33
Deviations from our protocol
Post hoc we included trials using the Chinese Classifica-
tion of Mental Disorders (CCMD) as well as a few trials 
including participants classified as having ‘minor depres-
sion’. The CCMD system closely adhere to the ICD and 
DSM systems and have been found highly compatible in 
field studies, so these studies were included.34 A few trials 
included some participants classified as having ‘minor 
depression’ according to the trials chosen diagnostic 
system (eg, DSM), and it is questionable if these partic-
ipants have major depression. We therefore decided to 
include these trials and to conduct a subgroup analysis 
exclusively including participants with major depres-
sion. To further explore heterogeneity, we post hoc 
included subgroup analysis comparing intervention 
effects in inpatients and outpatients as well as an anal-
ysis according to trial size. Trials were divided into small 
or large trials using the median of total n included in 
the efficacy analysis. The effect of exercise capacity was 
post hoc assessed by comparing trials with a high increase 
in maximal oxygen uptake (VO2max) with studies with 
lower increase in maximal oxygen uptake. Assessment of 
exercise capacity was based on the increase of VO2max in 
the intervention groups and trials were stratified to either 
high or low increase in exercise capacity by median. We 
did not conduct trial sequential analysis based on a rela-
tive risk reduction of 30% of lack of remission as this was 
an implausible effect.
Participant involvement
Depressed participants were not involved in this study.
rEsults
bibliographical search and trial characteristics
The main bibliographical search was conducted on 
26 August 2015 and the final updates were conducted 
on 20 June 2017. As illustrated in online supplemen-
tary figure S1, we identified 45 publications reporting 
the effect of exercise on depressive symptoms in 35 
randomised clinical trials.21 22 35–78 Seventeen trials were 
conducted in Europe,21 22 40 49 52 53 55 61 65–68 74 75 77 79 80 
eight in the USA,38 39 43 45 60 64 76 81 six in Asia,47 69–73 two 
in Australia54 58 and two in South America.56 63 A total 
of 2630 participants were randomised and 2498 were 
included in the efficacy analysis of benefit. Ten trials 
included inpatients47 49 56 67 69–73 79 and five trials included 
participants with a mean age >60 years.52 54 58 60 61 No trials 
exclusively included participants with comorbid somatic 
disease. Four trials reported the continuous outcome as 
mean change from baseline in each group with a corre-
sponding SD,39 53 65 68 and one trial presented data as 
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mean difference between groups postintervention.40 The 
remaining trials reported postscores in each group with 
corresponding SD (see table 1 for trial characteristics).
bias risk assessment
Sequence generation was adequate in 15/35 (43%), 
allocation concealment was adequate in 13/35 (37%) 
trials, blinding of participants and trial personnel was 
adequate in 0/35 (0%), blinded outcome assessment was 
performed in 16/35 (46%), low risk of bias in the ‘incom-
plete outcome data’ domain was found in 12/35 (34%) 
trials, selective outcome reporting domain was adequate 
in 31/35 (89%), for-profit bias domain was adequate in 
19/35 (54%) and 25/35 (71%) were free of other bias. 
Accordingly, all trials were at high risk of bias. Given the 
nature of the intervention, no trial had blinded partici-
pants or trial personnel, however, two trials had low risk 
of bias in all other bias domains.22 54 Five trials (16%) 
were sponsored by for-profit organisations: three trials 
were supported by pharmaceutical companies,53 79 82 one 
trial by a company producing fitness machines45 and one 
trial by an insurance company.21 According to our a priori 
defined criteria, 4/35 (11%) trials potentially had less 
risk of bias than the other trials at high risk of bias21 22 54 56 
(see table 2 for details on assessment of risk of bias).
Primary outcomes
The effect of exercise on depression severity
All included trials provided a continuous outcome on 
depression severity for the assessment of the exercise 
intervention encompassing 2498/2630 randomised 
participants (95%). The effect of intervention versus 
control was a SMD of −0.66 (95% CI −0.86 to −0.46; 
p<0.001) (figure 1). This corresponds to an effect on the 
HAM-D17 scale of −4.1 (95% CI −5.3 to −2.9) points.
Missing data
Missing outcome analysis for depression as a continuous 
outcome did not markedly change the effect estimates. The 
least favourable outcome for the exercise intervention was 
the worse/best outcome analysis using +2 SD resulting in 
an effect estimate of −0.57 SMD (95% CI −0.78 to −0.36; 
p<0.001) (see online supplementary table S1).
Heterogeneity and subgroup analysis
The I2 was 81% suggesting substantial heterogeneity. 
Subgroup analysis revealed that the effect estimates for 
trials potentially having less risk of bias was −0.11 SMD 
(95% CI −0.41 to 0.18; p=0.45; I2=62%) compared with 
that of the trials at high risk of bias −0.75 SMD (−0.98 
to −0.52; p<0.001; I2=81%) (test of subgroup difference, 
p<0.001). In addition, trials including 50 participants 
or less had a pooled estimate of −1.11 (-1.52 to −0.72; 
p<0.001; I2=78%) compared with that of larger trials of 
−0.37 (-0.57 to −0.18; p<0.001; I2=75%) (test of subgroup 
difference, p=0.001). Trials of short duration of interven-
tion (<10 weeks) had an SMD of −0.92 (−1.09 to −0.74; 
p<0.001; I2=14%) compared with trials with longer 
duration of intervention, −0.49 (-0.75 to −0.23; p<0.001; 
I2=83%) (test of subgroup difference, p=0.007). Effect 
estimates from trials including participants with minor 
depression compared with trials exclusively including 
participants with major depression did not differ (test of 
subgroup difference, p=0.53).
Four trials allocated 206 participants to different exer-
cise intensities/doses.45 58 73 83 Comparing the postinter-
vention depression scores for participants allocated to 
either high-intensity/high-dose versus low-intensity/
low-dose exercise showed a difference of −0.40 SMD 
(95% CI −0.67 to −0.12; p=0.005; I2=0%) in favour of 
high-intensity/high-dose exercise. As shown in table 3, no 
other trial characteristic significantly explained any of the 
observed heterogeneity (see online supplementary table 
S2 for trial characteristics used to explore heterogeneity.
Trial sequential analysis and diversity adjusted required 
information size
The diversity adjusted required information size for 
HAM-D17 as a continuous outcome was calculated based on 
our anticipated intervention effect of a minimal relevant 
difference of 3.0 HDRS points, an SD of 6.78 points, a risk 
of type I error of 0.05, a power of 90% and the observed 
diversity of 92% to 2610 participants. Only 14 trials reported 
results from HAM-D17
21 22 38 39 43 44 52 53 55 56 58 68 70 83 with an 
accrued 1124 participants. As shown in online  supple-
mentary figure S2, the cumulative Z-curve just crossed the 
trial sequential monitoring boundary for benefit. With the 
aforementioned settings, the pooled estimate is therefore 
less likely to be a random finding due to lack of power or 
multiple testing if bias could be ignored. Post hoc, we calcu-
lated the adjusted required information size for HAM-D17 
including all trials as shown in online supplementary figure 
S3. As with the original analysis, the Z-curve crossed the trial 
sequential monitoring boundary for benefit supporting that 
the pooled estimate is less likely to represent a type 1 error 
if bias could be ignored.
Bayes factor
Fourteen trials reported effect estimates using the 
HAM-D17.
21 22 38 39 43 45 52 53 55 63 68 70 83 84 Based on these 
trials, Bayes factor was calculated (δ=−3.37; SEδ=0.96; 
µa=−3.0) and was found to be 0.002, which is below the 
Bayes factor threshold for significance of 0.1, supporting 
the intervention effect if bias could be ignored.
Publication bias
Inspection of the funnel plot (not shown) suggested 
that small trials with small or no effect of exercise were 
missing (see online supplementary figure S4). Egger’s test 
supported the suspicion of publication bias, p<0.00001. 
Using the Duval’s and Tweedie’s trim and fill procedure, 
the estimate was reduced into −0.27 SMD (95% CI −0.50 
to −0.05). This corresponds to an effect on the HAM-D17 
scale of −1.7 (95% CI −3.1 to −0.31) points.
the effect of exercise on depression—lack of remission
Nineteen trials, randomising 1825 participants and 
including 1639 participants (90%) in final analysis 
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reported remission as an outcome.21 22 38–40 43 45 47 49 53 54 
56 60 61 65 68–70 72 Remission postintervention was defined in 
various ways: a postintervention score on the HAM-D17<8 
points,44 53 56 69 70 not fulfilling the DSM criteria for depres-
sion and a HAM-D17<8 points,
21 22 39 not fulfilling the DSM 
criteria for depression,38 54 60 a BDI score <9 points,43 a BDI 
score <10 points,40 a HAM-D17 score <10 points,
83 a Mont-
gomery-Asberg Depression Rating Scale (MADRS) score 
<10 points,47 a MADRS score <10 points and a 50% reduc-
tion in symptom score,65 a 75% reduction in HAM-D24,
72 
a HAM-D17 score <11.28 points and a reduction in 
HAM-D17 scores >7.74 points
68 and one study used MADRS 
not specifying the cut-off for remission.49 The RR for lack 
of remission was 0.78 (95% CI 0.68 to 0.90; p=0.0008) in 
favour of the intervention using a random-effects analysis. 
The I2 was 69% suggesting substantial heterogeneity. The 
forest plot for the intervention effect on lack of remission 
is illustrated in online supplementary figure S5.
Missing data
The scenario in least favour of the intervention was the 
‘poor’ outcome analysis having an effect estimate of RR 
0.88 (95% CI 0.83 to 0.94; p=0.0002; I2=69%). As shown in 
online supplementary table S1, the remaining scenarios 
did not substantially differ from the main analysis.
Heterogeneity and subgroup analysis
I2 was 69% for the outcome lack of remission suggesting 
substantial heterogeneity. For this outcome, only two 
trials22 84 were considered as trials potentially having 
less risk of bias than the other trials at high risk of bias. 
The RR of these two trials was 0.95 (95% CI 0.74 to 
1.23; p=0.78) compared with 0.77 (96% CI 0.64 to 0.92; 
p=0.003) for trials at high risk of bias (test of subgroup 
difference, p=0.19). Trials including 52 participants 
or less in their final analysis had a RR of 0.62 (95% CI 
0.50 to 0.76; p<0.001; I2=45%) compared with 0.95 
(95% CI 0.80 to 1.12; p=0.52; I2=68%) for larger trials 
(test of subgroup difference, p=0.002). Also, trials with 
a duration of <10 weeks had a RR of 0.63 (95% CI 0.51 
to 0.77; p<0.001; I2=40%) compared with 0.93 (95% CI 
0.78 to 1.10; p=0.39; I2=69%) for trials of a longer dura-
tion (test of subgroup difference, p=0.004). As shown in 
online supplementary table S3, no other trial character-
istic significantly explained any of the observed hetero-
geneity (see online supplementary table S2 for trial 
characteristics used to explore heterogeneity).
Trial sequential analysis and diversity adjusted required 
information size
The diversity adjusted required information size for lack 
of remission was calculated based on our observed diver-
sity of 74%, a proportion in the control group with lack 
of remission of 66%, an anticipated intervention effect of 
15% relative risk reduction, a risk of type I error of 0.05% 
and a power of 90%. As shown in online supplementary 
figure S6, the cumulative Z-curve just crossed the trial 
sequential monitoring boundary for benefit. With the 
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Figure 1 Effect of exercise on depression severity in patients diagnosed with depression.
aforementioned settings, the pooled estimate is therefore 
less likely to be a random finding due to lack of power or 
multiple testing if bias could be ignored.
Bayes factor
Bayes factor was calculated based on the observed relative 
risk of remission, the associated SE and an anticipated 
intervention effect of relative increase in number of 
participants with remission by 15% (δ=−0.248; SEδ=0.08; 
µδ=−0.163). Bayes factor was 0.02, which is below the 
Bayes factor threshold for significance of 0.1.
Publication bias
Inspection of the funnel plot (not shown) suggested 
that small trials with small or no effect of exercise were 
missing. Egger’s test supported the suspicion of publi-
cation bias, p=0.002. Imputing theoretically missing 
studies by the Duval’s and Tweedie’s trim and fill proce-
dure, reduced the estimate of intervention effect into 
a relative risk reduction of 0.93 (95% CI 0.79 to 1.11).
the effect of exercise on serious adverse events
Serious adverse events (ie, death or suicide attempts) 
were reported in only three trials.21 22 58 In these trials, 
one suicide attempt22 and one death by suicide21 were 
recorded in the intervention groups. The RR for death 
or suicide in the two trials was 2.21 (95% CI 0.24 to 
20.21; p=0.48; I2=0%) as illustrated in online supple-
mentary figure S7.
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Table 3 Heterogeneity of effect estimates for trials assessing the effect of exercise for patients diagnosed with depression 
explored by comparing subgroups
Subgroups
Number of
trials (participants)
Random-effects meta-analysis
SMD (95% CI, p, I2)
Subgroup explains 
heterogeneity
p Value
Risk of bias
  Less than high risk of bias1 4 (530) −0.11 (−0.41 to 0.18; p=0.45; I2=62%) <0.001
  High risk of bias 31 (1968) −0.75 (−0.98 to −0.52; p<0.001; I2=81%)
Age
  Old (>59 years) 5 (492) −0.77 (−1.34 to −0.19; p=0.009; I2=87%) 0.78
  Young (<59 years) 30 (2006) −0.68 (−0.90 to −0.45; p<0.001; I2=83%)
Exercise context
  Group exercise 26 (1785) −0.75 (−1.01 to −0.50; p<0.001; I2=83%) 0.30
  Individual exercise 9 (713) −0.52 (−0.88 to −0.16; p=0.005; I2=73%)
Duration
  <10 weeks 15 (721) −0.92 (−1.09 to −0.74; p<0.001; I2=14%) 0.007
  10 weeks or more 20 (1777) −0.49 (−0.75 to −0.23; p<0.001; I2=83%)
Attention control
  Attention control 10 (733) −0.56 (−0.98 to −0.15; p=0.008; I2=85%) 0.91
  Waitlist 2 (47) −0.67 (−2.48 to 1.13; p=0.47; I2=88%)
Pharmacotherapy
  Add-on 11 (734) −0.92 (−1.38 to −0.46; p<0.001; I2=86%) 0.82
  No medication 6 (318) −0.82 (−1.58 to −0.06; p=0.03; I2=88%)
Somatic comorbidity
  Somatic comorbidity 0 N/A
  No comorbidity 35 (2331) N/A
Minor depression
  Including minor depression 6 (350) −0.90 (−1.65 to −0.15; p=0.02; I2=86%) 0.53
  No minor depression 25 (2148) −0.65 (−0.87 to −0.43; p<0.001; I2=81%)
Patient setting
  Inpatients 10 (549) −0.88 (−1.07 to −0.70; p<0.001; I2=6%) 0.07
  Outpatients 21 (1782) −0.60 (−0.85 to −0.35; p<0.001; I2=83%)
Trial size
  Trials n≤50 18 (578) −1.11 (−1.52 to −0.72; p<0.001; I2=78%) 0.001
  Trials n>50 17 (1920) −0.37 (−0.57 to −0.18; p<0.001; I2=75%)
Increase in exercise capacity
  VO2max>2.8 mL/kg/min 5 (340) −0.48 (−1.08 to 0.13; p=0.12; I
2=86%) 0.65
  VO2max≤2.8 mL/kg/min 6 (661) −0.32 (−0.61 to 0.02; p=0.03; I
2=68%)
 VO2max, maximal oxygen uptake.
Missing data
Missing outcome analysis for ‘serious adverse events’ 
varied according to missing data scenario: poor 
outcome analysis relative risk, 0.92 (95% CI 0.37 to 
2.30; p=0.86; I2=60.0%), good outcome analysis, 2.19 
(95% CI 0.23 to 20.76; p=0.50; I2=0.0%), best/worst 
outcome analysis 0.08 (95% CI 0.02 to 0.34; p=0.001; 
I2=5.4%), worst/best outcome analysis 19.17 (95% CI 
2.64 to 139.2; p=0.004; I2=0.0%).
Trial sequential analysis and Bayes analysis
We decided not to conduct trial sequential analysis or 
Bayes analysis due to too sparse data.
Publication bias
Only 3/35 trials reported on this outcome and no formal 
assessment for publication bias was made. However, the 
lack of reporting in the vast majority of trials suggest risk 
publication bias.
secondary outcomes
The effect of exercise on quality of life
Nine trials randomising 827 participants reported on 
quality of life,21 22 38 40 56 60 71 76 85 observing that partic-
ipants allocated to exercise did not have significantly 
better quality of life (SMD 0.40; 95% CI −0.03 to 0.83; 
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p=0.07). The I2 was 88% showing substantial hetero-
geneity (see online supplementary figure S8).
Non-serious adverse events
Non-serious adverse events were reported in only 10 
trials.21 22 39 56 58 60 65 67 68 75 Five trials reported on muscu-
loskeletal adverse events without conducting formal 
tests58 60 65 67 68 and four trials reported on number of 
participants with high depression scores postintervention 
compared with baseline assessment.21 22 65 68 The RR for 
increased severity of depression in patients allocated to 
exercise postintervention was 0.83 (95% CI 0.40 to 1.70; 
p=0.60; I2=0.0%).
The effect of exercise on depression beyond the duration of the 
intervention
Assessment of depression beyond the intervention was 
conducted in seven trials,21 38 40 52 60 63 86 with a median 
duration between end of intervention and assessment of 
depression of 6 months (range 5–23.5 months). The SMD 
between the intervention group and the control group 
using a random-effects analysis was −0.10 (95% CI −0.28 
to 0.09; p=0.31; I2=19.5%). The I2 for this estimate was 
19.5% suggesting low heterogeneity (see online supple-
mentary figure S9).
Remission beyond the intervention was assessed in five 
trials,21 38–40 54 and the relative risk of lack of remission was 
0.95 (95% CI 0.82 to 1.11; p=0.53) with an I2 of 0.0% (see 
online supplementary figure S10).
GRADE assessments
The GRADE assessments are presented in table 4, and 
quality of evidence for both primary and secondary 
outcomes was very low or low.
Additional analysis
Four studies reported change in scores from baseline with 
corresponding SDs, and one study reported mean differ-
ence between groups postintervention. Comparing the 
effect size of these five studies with the remaining did not 
seem to explain part of the heterogeneity (p=0.23).
DIscussIOn
Thirty-five clinical trials allocating more than 2498 partic-
ipants diagnosed with depression according to validated 
diagnostic instruments were included in the present 
systematic review. Pooled estimates suggested moderate 
antidepressant effect assessed both as a continuous 
outcome and as lack of remission. Due to risk of bias, 
inconsistency of effect estimates and publication bias, 
we have, however, very little confidence in these effect 
estimates. Subgroup analyses exploring reasons for the 
heterogeneity found that trials potentially having less risk 
of bias than other trials at high risk of bias had no effect 
of exercise on depression. Furthermore, duration of 
intervention and trial size were inversely associated with 
effect estimates. Exercise did not improve quality of life 
or depression or remission after the intervention. Serious 
adverse events or adverse events were reported inconsis-
tently and only by a few trials not permitting firm conclu-
sions regarding these outcomes.
strengths and limitations
The strengths of this systematic review are that it is 
based on the published protocol, a comprehensive 
search strategy and the inclusion of patient-centred 
outcomes such as quality of life as well as adverse 
events. Also, to avoid spurious finding from repeated 
testing, trial sequential analysis and Bayes analysis were 
undertaken and these analyses did not suggest that the 
pooled estimates could be reduced to random errors for 
effect on depression severity or no remission. Neither 
trial sequential analysis nor Bayes factor analysis are, 
however, able to wash of spurious effects induced by 
bias, fraud or other reasons.26 29 87–89 Had we restricted 
the trial sequential analysis to trials of potentially 
lower risk of bias, the number of trials and participants 
would be limited and we had seen evidence far from 
crossing any boundaries for benefit, harms or futility. 
The conclusions for serious adverse events and adverse 
events were associated with wide CIs due to lack of data 
and firm conclusions for these outcomes are presently 
not available.
The number of trials with adequate allocation conceal-
ment was 37% in the current systematic review compared 
with only 15.1% in trials assessing non-drug interven-
tions for depression.90 Blinded outcome assessment was 
performed in 46% of the included trials compared with 
44% in non-drug antidepressant trials in general.90 The 
incomplete outcome bias domain was adequate in 34% of 
our included trials compared with 32.9% of antidepres-
sant non-drug trials in general.90Compared with non-drug 
trials assessing interventions for participants with depres-
sion, the included exercise trials have more bias domains 
with low risk of bias. However, all our included trials 
were at high risk of bias. Two trials had low risk of bias 
for all bias domains except for blinding of participants 
and trial personnel, and four trials fulfilled our criteria 
for trials at potentially less risk of bias than the rest of 
the trials with at risk of bias. Despite a search strategy 
including bibliographical databases and trials from China 
and South America, the vast majority of included trials 
were conducted in North America and western Europe, 
which is comparable to the geographical distribution of 
non-drug trials in general,90 limiting the applicability to 
other geographic regions.
All outcomes for the primary analysis reflect depres-
sion severity, however, the different psychometrics may 
represent different aspects of depression not reflected 
in the pooled estimate. An in-depth discussion of the 
included assessment scales is beyond the scope of this 
review, but in the current systematic review we found no 
significant differences of effect estimates from trials using 
HAM-D17 compared with trials using other assessment 
scales (data not shown).
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the effect of exercise on depression
Our present results are similar to the latest Cochrane 
review by Cooney et al,24 who found a moderate effect 
of exercise on depressive symptoms (−0.62 SMD) when 
including all trials and no effect when restricting the 
analysis to trials with less risk of bias (−0.18 SMD). The 
Cochrane review did find evidence of a small antidepres-
sant effect beyond the intervention, which we could not 
confirm in our present systematic review. Bridle et al13 
included nine trials allocating old (>60 years) participants 
with depression to exercise interventions versus control 
interventions. Restricting the analysis to four trials at 
lower risk of bias they found small-to-moderate effect 
estimates (SMD −0.34) in favour of exercise. The studies 
by Cooney et al24 and Bridle et al13 both included trials 
allocating participants with depressive symptoms and not 
necessarily diagnosed using a validated diagnostic system, 
potentially explaining the differences in the effect sizes. 
However, in our present systematic review the estimate for 
four trials at potential less risk of bias than the remaining 
trials was −0.11 SMD and in the study by Cooney et al, the 
effect estimate for eight trials with lower risk of bias was 
−0.18 SMD24 compared with −0.34 in the study by Bridle 
et al.13 Meta-analysis of randomised clinical trials assessing 
the effects of exercise for depression consistently finds 
positive effects, however, when restricting the analysis to 
trials with less risk of bias the pooled effect sizes becomes 
very small or negligible. Meta-analysis examining the 
effect of exercise beyond the intervention also finds no 
or small effects of exercise. In the process of interpreta-
tion of effect estimates in the current research field, it 
is important to recognise that effect estimates from trials 
with non-blinded outcome assessment are at high risk of 
bias as reported by Savović et al.91 Sixteen of 35 trials in the 
current systematic review did not use blinded outcome 
assessment. In contradiction to the current systematic 
review, a recent meta-analysis by Schuch et al12 concluded 
that 'exercise has a large and significant antidepressant 
effect in people with depression………Our data strongly 
support the claim that exercise is an evidence-based 
treatment for depression’. This statement was based on 
a meta-analysis of 25 randomised clinical trials including 
participants with depression or depressive symptoms 
to exercise or control conditions and excluding trials 
using any form of active control group. Surprisingly, the 
authors found that adjusting for publication bias using 
the trim and fill procedure,31 the estimate increased from 
an SMD of 0.98 to 1.11. The effect in SMD in included 
studies ranged from −0.23 to 4.56 representing consid-
erable heterogeneity.12 The authors classified four trials 
as having lower risk of bias using the same criteria as in 
our systematic review and 21 trials as having high risk of 
bias. This illustrates some of the challenges in meta-anal-
ysis of exercise and depression: the large heterogeneity 
driven by small studies inflating the effects of random-ef-
fects analysis,92 the misconception that we can restrict 
our analysis to statistics and not consider the evident 
effect of bias.23 91 Compared with our previous review,10 
we now included 35 trials including 2498 participants 
versus previously 13 trials and 687 participants. It may 
seem as a paradox that this large increase in data has not 
provided us with a similar increase in certainty of conclu-
sions reflected by heterogeneity of trial results as well as 
our conclusions from the systematic reviews. The increase 
in available data is, however, primarily provided by small 
trials at high risk of bias introducing exaggerated effect 
estimates. In the current systematic review, we included 
four trials with 530 participants at lower risk of bias 
compared with three trials with 239 participants in our 
previous review, reflecting that only a small part of the 
additional data comes from trials at lower risk of bias. The 
continuous increase in data associated with high risk of 
bias will not provide patients, clinicians or policymakers 
with adequate information and represents an unethical 
enrolment of trial participants and waste of resources.93–99 
We therefore recommend that future systematic reviews 
and meta-analysis a priori should have a primary outcome 
restricting effect analysis to larger trials with lower risk 
of bias and that any recommendations regarding exercise 
interventions for participants with depression should be 
assessed with the GRADE framework.
The I2 of 81% and 69% for the primary outcomes indi-
cate substantial evidence of heterogeneity of intervention 
effects that is variation in effect estimates beyond chance. 
Part of this heterogeneity was explained by bias and by 
trial size: trials at high risk of bias or small trials have 
very large effect estimates compared with trials poten-
tially at less risk of bias or larger trials. The funnel plots 
and Egger’s test indicate publication bias, however, the 
association between trial size and effect estimates could 
suggest that the asymmetry in the funnel plots are due to 
small study bias rather than publication bias.100 It could 
be argued that both the delivery of exercise as well as the 
actual increase in fitness are fundamental to the assess-
ment of the antidepressant effects of exercise, and in line 
with our previous review, we found duration of interven-
tion inversely associated with effect size.11 Comparing 
different exercise intensities, we did find a small effect 
of high-intensity exercise compared with lower-intensity 
exercise. However, assessing delivered exercise expressed 
as increase in maximal oxygen uptake we could not repro-
duce this finding. Future trials need to pay more attention 
to the dose of the intervention as well as compliance with 
intervention.101 We suggest using maximal oxygen uptake 
or one repetition maximum as the gold standard to assess 
the received exercise. Several studies compare exercise 
with control interventions rather than waitlist control to 
reduce the effect of non-specific effects, for example, the 
DEpression og MOtion (DEMO) trials and the trials by 
Mather et al.21 22 52 Also, it could be speculated that the 
effect of exercise would be harder to detect if partici-
pants also received medical treatment in addition. The 
current systematic review could not confirm that the type 
of control condition explained heterogeneity. The discus-
sion of control group is important in non-drug trials: 
choosing a waitlist control group the results potentially 
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reflects non-specific effects, choosing an active control 
group (eg, relaxation exercise) the trial is potentially a 
comparison between two active treatments. However, 
in the current systematic review we found no evidence 
that trials using an attention control group or exercise 
as add-on to pharmacotherapy had significantly different 
effect estimates compared with other trials.
Our systematic review did not find indications of a posi-
tive effect on quality of life in participants with depression 
allocated to exercise interventions, which is in concor-
dance with the review by Cooney et al.24 Only 3/35 trials 
reported on serious adverse events, and we found no 
significant effects of exercise on risk of death or suicide 
attempt. No indication of increased severity of depres-
sion or other adverse events in participants allocated to 
exercise could be detected. However, data on adverse 
events were reported sporadically in a minority of trials 
and currently it is not possible to conclude on the risk 
of serious adverse events or adverse event from exercise 
interventions in participants with depression.
cOnclusIOns
We have little confidence in the pooled effect estimates, 
especially because trials with less than high risk of bias 
produced significantly lower effect estimates, suggesting 
that exercise interventions only produce small or negli-
gible antidepressant effects, depending on how much 
of the effect is caused by bias and how much is caused 
by the intervention. There was no effect of exercise on 
depression beyond the intervention itself. We found no 
effect on quality of life. There is currently no evidence in 
favour of exercise for patients with depression with a view 
to ameliorate depressive symptoms. Our systematic review 
did not evaluate possible beneficial effects of exercise on, 
for example, metabolism or cardiovascular fitness,22 102 
and it is possible that exercise may have beneficial effects 
on these factors in patients diagnosed with depression.
Future perspectives
Despite the large number of published trials, further 
trials with more robust methodology seem still required 
to establish progress in this field. Also, additional trials 
from outside North America and Europe may be required 
for results to be valid for patients in Asia, Africa and 
South America. To further elaborate on the current 
findings, we recommend that future trials must include 
blinded outcome assessors and outcomes assessing quality 
of life, metabolic effects and long-term effects beyond 
the intervention. It is also important that future trials 
systematically collect and report data on death, suicide 
events, musculoskeletal injuries and other potential 
adverse effects in both the intervention group as well as 
in the control group. Moreover, future trials ought to be 
designed according to the standard protocol items: recom-
mendations for interventional trials (SPIRIT) guidelines 
and reported according to the consolidated standards 
for reporting of trials (CONSORT) guidelines103 104 and 
transparently report deidentified individual participant 
data enabling individual participant data meta-analyses.105
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